Mylan is recalling three lots of its ulcer treatment after detecting trace amounts of a carcinogen in the product.
Nizatidine, intended for the short-term treatment of duodenal ulcers and benign gastric ulcers, was found to contain the impurity N-nitrosodimethylamine.
The affected lots were distributed to wholesalers, mail order pharmacies and retail pharmacies between June 2017 and August 2018.
Mylan said it hasn't received any adverse event reports related to the recall.
Read the full news release here.